Analyst Price Target is $5.60
▲ +543.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Clearside Biomedical in the last 3 months. The average price target is $5.60, with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 543.75% upside from the last price of $0.87.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Clearside Biomedical. This Buy consensus rating has held steady for over two years.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.